Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,547 INR
Change Today +19.05 / 0.54%
Volume 215.4K
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Mexico
Frankfurt
As of 3:32 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
3,565
Previous Close
3,528
Day High
3,573
Day Low
3,490
52 Week High
04/10/15 - 3,809
52 Week Low
06/5/14 - 2,291
Market Cap
604.5B
Average Volume 10 Days
276.0K
EPS TTM
130.22
Shares Outstanding
170.3M
EX-Date
--
P/E TM
27.3x
Dividend
20.00
Dividend Yield
0.51%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Ltd. Wins GBP 230 Million Multiple Awardees Contract for Supplying Generic Pharmaceuticals

Dr. Reddy's Laboratories Ltd. has won a GBP 230 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic pharmaceuticals.

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day

Dr. Reddy's Laboratories Limited Recommends Final Dividend for the Financial Year 2014-15

Dr. Reddy's Laboratories Limited has informed that the Board of Directors of the company at its meeting held on May 12, 2015 have recommended a final dividend of INR 20 (400%) per equity share of INR 5 face value, for the financial year 2014-15.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 3,546.20 INR +18.25

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,839 INR -27.25
Cipla Ltd/India 649.25 INR +5.25
Croda International PLC 2,973 GBp -4.00
Endo International PLC $82.94 USD -0.47
Symrise AG €57.62 EUR -0.355
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 26.7x
Price/Sales 4.0x
Price/Book 5.3x
Price/Cash Flow 26.6x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.